Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections.

OBJECTIVE To evaluate the relation between CD4 and HIV RNA levels at the onset of specific opportunistic infections (OIs) in HIV-infected patients. DESIGN AND METHODS The OIs occurring between June 1996 and December 1998 were retrospectively reviewed, considering only the episodes of major and minor OIs in patients with simultaneously available CD4 and plasma HIV RNA determinations before clinical onset who had been untreated or on stable antiretroviral therapy (ART) for at least 2 months. RESULTS Two hundred seventy-four episodes of different OIs were considered in 216 patients; the median CD4 count was 35 cells/mm3 (range: 0-1154 cells/mm(3)), and the median HIV RNA count was 5.1 log cp/mL (range: < 1.9-6.7 log copies/ml). The different HIV RNA levels were significantly associated with different OIs regardless of CD4 and ART (p < .0001), even when only those occurring in patients with a CD4 count of < or = 50 cells/mm(3) were considered (p = .0049). Kaposi sarcoma, esophageal candidiasis, oropharyngeal candidiasis, and Mycobacterium avium complex disease were associated with significantly above-average median HIV RNA levels, and varicella-zoster virus infection was associated with below-average levels. CONCLUSIONS Different OIs are associated at their onset with significantly different HIV RNA levels, regardless of CD4 cell counts and ART.

[1]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[2]  R. Chaisson,et al.  Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.

[3]  W. Powderly The interaction of opportunistic infections and HIV replication. , 1999, AIDS.

[4]  S. Swindells,et al.  Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. , 1999, AIDS.

[5]  J. Margolick,et al.  Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex , 1999 .

[6]  E. Bouza,et al.  Treatment of AIDS‐associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy , 1998, AIDS.

[7]  J. Gatell,et al.  High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Cinque,et al.  Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. , 1998, The New England journal of medicine.

[9]  J. McGowan,et al.  Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. , 1998, AIDS.

[10]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[11]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[12]  D. Cooper,et al.  Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy , 1998, The Lancet.

[13]  F. Fazio,et al.  Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography. , 1997, AIDS.

[14]  J. Harrington,et al.  Repetitive strain injuries , 1997, The Lancet.

[15]  C. Wood,et al.  Activation of HHV-8 by HIV-1 tat , 1997, The Lancet.

[16]  J. Goedert,et al.  Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.

[17]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[18]  J. Ward,et al.  Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. , 1995, Archives of internal medicine.

[19]  J. Ward,et al.  Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses , 1995 .

[20]  L. Gergely,et al.  Interactions between human immunodeficiency virus type 1 and human cytomegalovirus in human term syncytiotrophoblast cells coinfected with both viruses , 1995, Journal of virology.

[21]  J. Phair,et al.  Thrush and Fever As Measures of Immunocompetence in HIV‐1-Infected Men , 1994, Journal of acquired immune deficiency syndromes.

[22]  D. van Strijp,et al.  A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. , 1994, Journal of virological methods.

[23]  P. Selwyn,et al.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. , 1992, The New England journal of medicine.

[24]  D. Fuchs,et al.  Markers for disease progression in intravenous drug users infected with HIV-1. , 1991, AIDS.

[25]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[26]  D. Lanska,et al.  Progressive multifocal leukoencephalopathy in patients with HIV infection. , 1998, Journal of neurovirology.

[27]  B. Andersen,et al.  Human immunodeficiency virus and Mycobacterium avium complex coinfection of monocytoid cells results in reciprocal enhancement of multiplication. , 1995, The Journal of infectious diseases.